Highlights
Dual-Mechanism Efficacy
APG-2449 acts as both a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) and a focal adhesion kinase (FAK) inhibitor, addressing resistance pathways that often bypass traditional TKI therapy.
Clinical Response in Resistant Disease
In patients resistant to second-generation ALK inhibitors, APG-2449 achieved an objective response rate (ORR) of 45.5% and a median progression-free survival (mPFS) of 13.6 months.
Exceptional CNS Penetration
Pharmacokinetic data confirmed significant blood-brain barrier penetration, with an intracranial ORR of 75.0%, addressing a critical need for patients with brain metastases.
Biomarker Synergy
Higher baseline levels of phosphorylated FAK (pFAK) were strongly correlated with improved clinical outcomes, suggesting pFAK as a potential predictive biomarker for treatment selection.
Background: The Evolution of ALK-Positive NSCLC Therapy
The management of anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) has been transformed by the development of sequential generations of tyrosine kinase inhibitors (TKIs). While first-generation (crizotinib) and second-generation (alectinib, brigatinib, ceritinib) agents have significantly improved survival, the emergence of resistance remains an inevitable clinical hurdle. Resistance typically arises through secondary mutations in the ALK kinase domain or the activation of bypass signaling pathways.
Focal adhesion kinase (FAK) has emerged as a key mediator in these bypass pathways. Elevated FAK activity is often associated with increased tumor invasiveness, survival, and, crucially, resistance to ALK inhibitors. APG-2449 is a first-in-class, orally bioavailable, small-molecule inhibitor designed to target ALK, ROS1, and FAK simultaneously. By inhibiting FAK, APG-2449 aims to not only suppress primary oncogenic signaling but also neutralize a major escape route used by cancer cells to survive TKI pressure.
Study Design and Methodology
This multicenter, open-label, single-arm phase 1 trial (NCT03917043) was conducted to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of APG-2449. The study followed a traditional 3 + 3 dose-escalation design, with doses ranging from 150 mg to 1500 mg administered once daily in 28-day cycles.
Following the determination of the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D), a dose-expansion phase was initiated. The expansion cohorts included patients with second-generation TKI-treated ALK+ NSCLC, TKI-naïve ALK+ NSCLC, and both TKI-naïve and TKI-treated ROS1+ NSCLC. Eligible participants were required to have an ECOG performance status of 0 or 1 and adequate organ function. Notably, patients with stable brain metastases were included, allowing for an assessment of the drug’s intracranial activity.
Key Findings: Safety and Pharmacokinetics
Between May 2019 and April 2024, 144 patients were enrolled. The dose-escalation phase determined that the MTD was not reached even at 1500 mg/day; however, based on the overall safety and PK profile, 1200 mg/day was established as the RP2D.
Safety Profile
APG-2449 demonstrated a manageable safety profile. The most frequent treatment-emergent adverse events (TEAEs) of grade 3 or higher were anemia (4.2%), increased alanine aminotransferase (ALT) (4.2%), QT prolongation (3.5%), and pneumonia (3.5%). Treatment-related adverse events (TRAEs) were generally reversible with dose interruptions or reductions. Importantly, no treatment-related deaths were reported, distinguishing it as a relatively well-tolerated option compared to some intensive chemotherapy regimens.
Pharmacokinetics and CNS Activity
Pharmacokinetic analysis revealed a dose-proportional increase in plasma exposure. A standout finding was the drug’s ability to cross the blood-brain barrier. The cerebrospinal fluid (CSF)-to-free plasma ratio ranged from 0.65 to 1.66, which is significantly higher than many earlier-generation TKIs. This PK profile translated into a robust intracranial ORR of 75.0% among 12 patients with brain metastases treated at the RP2D.
Clinical Efficacy: Bridging the Resistance Gap
The efficacy results were categorized by patient history and molecular status, providing clear insights into where APG-2449 fits in the treatment paradigm.
TKI-Naïve Patients
In the cohort of 14 patients with ALK-positive, TKI-naïve NSCLC treated at the RP2D, the ORR was 78.6%. At the time of reporting, the median progression-free survival (mPFS) had not yet been reached, indicating durable responses in the first-line setting.
Second-Generation TKI-Resistant Patients
Perhaps the most clinically significant data came from the 22 patients who had progressed on second-generation ALK inhibitors. In this subset (specifically those without ALK compound mutations or other complex bypass mechanisms), the ORR was 45.5%, and the mPFS was 13.6 months. This suggests that APG-2449 can effectively re-sensitize tumors to ALK inhibition by simultaneously blocking FAK signaling.
Expert Commentary: The Role of FAK in Precision Oncology
The association between baseline tumor pFAK levels and clinical benefit is a pivotal discovery of this trial. Patients with higher pFAK expression showed deeper and more prolonged responses to APG-2449. This validates the mechanistic hypothesis that FAK is a driver of resistance and suggests that pFAK could serve as a vital biomarker for identifying patients most likely to benefit from this triple-action inhibitor.
While Lorlatinib remains a standard third-generation option, it is primarily designed to overcome specific ALK resistance mutations (like G1202R). APG-2449 offers a complementary approach by targeting the FAK-mediated bypass signaling that Lorlatinib may not address. This study highlights the necessity of moving beyond a ‘one-size-fits-all’ approach to resistance, instead tailoring therapy to the specific molecular escape mechanism of the tumor.
Limitations of the study include its single-arm design and the relatively small sample sizes in specific sub-cohorts. Larger, randomized trials will be necessary to definitively place APG-2449 within the current treatment algorithms, particularly in comparison to other third-generation inhibitors.
Conclusion
APG-2449 represents a significant advancement in the targeted treatment of ALK+ and ROS1+ NSCLC. By combining ALK/ROS1 inhibition with FAK modulation, it provides a dual-threat approach that is effective in both treatment-naïve patients and those who have failed second-generation TKIs. Its exceptional brain penetration and manageable toxicity profile make it a strong candidate for further clinical development. As the field moves toward more personalized oncology, the integration of FAK inhibition marks a promising new chapter in overcoming TKI resistance.
Funding and Trial Information
This study was funded by Ascentage Pharma Group Corp Ltd. (Hong Kong). ClinicalTrials.gov Identifier: NCT03917043.
References
1. Ma Y, Song Z, Chen J, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK+ and ROS1+ non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial. EClinicalMedicine. 2025;89:103556.
2. Gainor JF, et al. Molecular Mechanisms of Resistance to Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discovery. 2016.
3. Sulzmaier FJ, et al. FAK in cancer: mechanistic findings and clinical applications. Nature Reviews Cancer. 2014.
